These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Intratympanic dexamethasone medication for sudden sensorineural hearing loss: clinical evaluation].
    Author: Shi J, Yang J, Wu H, Xue B, Chen X, Cao R, Meng G, Xiang M, Huang Q.
    Journal: Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Aug; 20(16):749-51. PubMed ID: 17058923.
    Abstract:
    OBJECTIVE: To investigate clinical efficacy of intratympanic dexamethasone injection for sudden sensorineural hearing loss. METHOD: Subjects received an course of at least 7-day dexamethasone [5 g/(L x d)] intratympanic injection. Pure-tone averages (PTA) calculated using air conduction thresholds at 4 -frequencies (500, 1000, 2000, 4000 Hz) at pre-injection and post-injection were compared. The change in PTA greater than 10 dB HL was considered to be effective. RESULT: PTA at pre-injection and post-injection were (65.65 +/- 24.73) dB HL and (50.25 +/- 25.59)dB HL respectively in 21 patients with sudden sensorineural hearing loss. There was significant improvement in PTA (P < 0.01). Improvement in hearing was found in 47.6% patients. Promising results of intratympanic dexamethasone medication were found in cases with shorter duration or/and without vertigo. No unexpected adverse events such as otitis media or perforated tympanic membrane or worsening in hearing occurred during the injection or follow-up period. CONCLUSION: Intratympanic dexamethasone medication can be beneficial in treating patient with sudden sensorineural hearing loss. Duration and vertigo are two important factors for prognosis.
    [Abstract] [Full Text] [Related] [New Search]